FDA's Oncologic Drugs Advisory Committee voted 14-1 to reject Eli Lilly's new lung cancer drug, in today's bite-sized hospital and health industry news from Maryland, Nevada, and Virginia.
Create your free account to access 2 resources each month, including the latest research and webinars.
You have 2 free members-only resources remaining this month remaining this month.
1 free members-only resources remaining this month
1 free members-only resources remaining this month
Never miss out on the latest innovative health care content tailored to you.